Published in Hum Gene Ther on August 30, 2011
Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies. Mamm Genome (2012) 1.28
Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr Opin Support Palliat Care (2013) 0.96
Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials. ILAR J (2014) 0.88
Duchenne muscular dystrophy gene therapy in the canine model. Hum Gene Ther Clin Dev (2015) 0.86
Genetic myostatin decrease in the golden retriever muscular dystrophy model does not significantly affect the ubiquitin proteasome system despite enhancing the severity of disease. Am J Transl Res (2013) 0.84
Impaired skeletal muscle regeneration in the absence of fibrosis during hibernation in 13-lined ground squirrels. PLoS One (2012) 0.78
Genetic disruption of Smad7 impairs skeletal muscle growth and regeneration. J Physiol (2015) 0.77
Dystrophin-deficient dogs with reduced myostatin have unequal muscle growth and greater joint contractures. Skelet Muscle (2016) 0.76
Prospect of gene therapy for cardiomyopathy in hereditary muscular dystrophy. Expert Opin Orphan Drugs (2015) 0.75
Circulating Biomarkers for Duchenne Muscular Dystrophy. J Neuromuscul Dis (2015) 0.75
Developmental Biology and Regenerative Medicine: Addressing the Vexing Problem of Persistent Muscle Atrophy in the Chronically Torn Human Rotator Cuff. Phys Ther (2016) 0.75
Activin Receptor Type IIB Inhibition Improves Muscle Phenotype and Function in a Mouse Model of Spinal Muscular Atrophy. PLoS One (2016) 0.75
Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature (1997) 14.82
Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med (2004) 7.80
The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science (1989) 6.80
The muscular dystrophies. Lancet (2002) 6.41
Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med (2004) 5.59
Functional improvement of dystrophic muscle by myostatin blockade. Nature (2002) 5.10
Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med (2002) 5.07
Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle. Genome Res (1997) 4.74
Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol (2004) 4.69
Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med (1999) 4.61
Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther (2001) 4.35
Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci U S A (2005) 3.52
Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol (2003) 3.46
Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol (2002) 3.03
Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol (2009) 3.01
Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve (2006) 2.98
A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol (2008) 2.95
Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther (2007) 2.76
Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol (2002) 2.76
Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science (2004) 2.71
Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases. Proc Natl Acad Sci U S A (2003) 2.66
Quadrupling muscle mass in mice by targeting TGF-beta signaling pathways. PLoS One (2007) 2.41
An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics (1992) 2.29
Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Sci Transl Med (2009) 2.21
Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. FASEB J (2005) 2.14
Myostatin directly regulates skeletal muscle fibrosis. J Biol Chem (2008) 2.11
Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury. Mol Ther (2005) 2.08
Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood (2007) 2.05
Canine X-linked muscular dystrophy. An animal model of Duchenne muscular dystrophy: clinical studies. J Neurol Sci (1988) 1.98
Contractile properties of EDL and soleus muscles of myostatin-deficient mice. J Appl Physiol (1985) (2006) 1.81
Characterization of alterations in diabetic myocardial tissue using high resolution MRI. Int J Cardiovasc Imaging (2005) 1.78
Myostatin propeptide gene delivery by adeno-associated virus serotype 8 vectors enhances muscle growth and ameliorates dystrophic phenotypes in mdx mice. Hum Gene Ther (2008) 1.65
Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs. Mol Ther (2010) 1.56
Body-wide gene therapy of Duchenne muscular dystrophy in the mdx mouse model. Proc Natl Acad Sci U S A (2006) 1.55
Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy. Biochim Biophys Acta (2010) 1.47
Myostatin does not regulate cardiac hypertrophy or fibrosis. Neuromuscul Disord (2007) 1.40
Persistent expression of FLAG-tagged micro dystrophin in nonhuman primates following intramuscular and vascular delivery. Mol Ther (2009) 1.35
Quantitative MR imaging of individual muscle involvement in facioscapulohumeral muscular dystrophy. Neuromuscul Disord (2009) 1.30
Canine X-linked muscular dystrophy in Japan (CXMDJ). Exp Anim (2003) 1.27
Read-through strategies for suppression of nonsense mutations in Duchenne/ Becker muscular dystrophy: aminoglycosides and ataluren (PTC124). J Child Neurol (2010) 1.23
Hydrodynamic limb vein injection of adeno-associated virus serotype 8 vector carrying canine myostatin propeptide gene into normal dogs enhances muscle growth. Hum Gene Ther (2009) 1.21
MR measurements of muscle damage and adaptation after eccentric exercise. J Appl Physiol (1985) (1999) 1.21
AAV-mediated delivery of a mutated myostatin propeptide ameliorates calpain 3 but not alpha-sarcoglycan deficiency. Gene Ther (2007) 1.17
Myostatin blockade improves function but not histopathology in a murine model of limb-girdle muscular dystrophy 2C. Muscle Nerve (2008) 1.17
Long-term benefit of adeno-associated virus/antisense-mediated exon skipping in dystrophic mice. Hum Gene Ther (2008) 1.17
Long-term skeletal muscle protection after gene transfer in a mouse model of LGMD-2D. Mol Ther (2007) 1.13
Changes in muscle T2 and tissue damage after downhill running in mdx mice. Muscle Nerve (2011) 1.13
Sprinting without myostatin: a genetic determinant of athletic prowess. Trends Genet (2007) 1.10
Systemic myostatin inhibition via liver-targeted gene transfer in normal and dystrophic mice. PLoS One (2010) 1.10
Evaluation of adeno-associated viral vectors for liver-directed gene transfer in dogs. Hum Gene Ther (2011) 1.05
Gene therapy in large animal models of muscular dystrophy. ILAR J (2009) 1.05
Activin IIB receptor blockade attenuates dystrophic pathology in a mouse model of Duchenne muscular dystrophy. Muscle Nerve (2010) 1.03
A duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient cavalier king charles spaniels is amenable to exon 51 skipping. PLoS One (2010) 0.98
Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy. Am J Pathol (2011) 0.98
Relative persistence of AAV serotype 1 vector genomes in dystrophic muscle. Genet Vaccines Ther (2008) 0.97
Origins and early descriptions of "Duchenne muscular dystrophy". Muscle Nerve (2003) 0.93
Gene therapy for muscle disease. Exp Cell Res (2010) 0.90
The potential of exon skipping for treatment for Duchenne muscular dystrophy. J Child Neurol (2010) 0.81
Matrix elasticity directs stem cell lineage specification. Cell (2006) 43.00
Myotubes differentiate optimally on substrates with tissue-like stiffness: pathological implications for soft or stiff microenvironments. J Cell Biol (2004) 7.38
PTC124 targets genetic disorders caused by nonsense mutations. Nature (2007) 6.67
The mechanism of myosin VI translocation and its load-induced anchoring. Cell (2004) 3.85
Mesenchymal stem cell injection after myocardial infarction improves myocardial compliance. Am J Physiol Heart Circ Physiol (2006) 3.78
A structural state of the myosin V motor without bound nucleotide. Nature (2003) 3.63
Three myosin V structures delineate essential features of chemo-mechanical transduction. EMBO J (2004) 3.21
Role of the lever arm in the processive stepping of myosin V. Proc Natl Acad Sci U S A (2002) 2.86
Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol (2002) 2.76
The structure of the myosin VI motor reveals the mechanism of directionality reversal. Nature (2005) 2.50
A model of myosin V processivity. J Biol Chem (2004) 2.49
Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy. Nat Med (2008) 2.49
Myostatin activation in patients with advanced heart failure and after mechanical unloading. Eur J Heart Fail (2010) 2.40
A force-dependent state controls the coordination of processive myosin V. Proc Natl Acad Sci U S A (2005) 2.39
Myosin VI steps via a hand-over-hand mechanism with its lever arm undergoing fluctuations when attached to actin. J Biol Chem (2004) 2.31
Effects of experimental weight perturbation on skeletal muscle work efficiency in human subjects. Am J Physiol Regul Integr Comp Physiol (2003) 2.28
Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum Gene Ther (2008) 2.27
Early quadriceps strength loss after total knee arthroplasty. The contributions of muscle atrophy and failure of voluntary muscle activation. J Bone Joint Surg Am (2005) 2.26
A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs. Mol Ther (2008) 2.22
Ambulatory continuous femoral nerve blocks decrease time to discharge readiness after tricompartment total knee arthroplasty: a randomized, triple-masked, placebo-controlled study. Anesthesiology (2008) 2.07
Neovasculogenic therapy to augment perfusion and preserve viability in ischemic cardiomyopathy. Ann Thorac Surg (2006) 1.82
Full-length myosin VI dimerizes and moves processively along actin filaments upon monomer clustering. Mol Cell (2006) 1.80
A flexible domain is essential for the large step size and processivity of myosin VI. Mol Cell (2005) 1.78
Total elbow arthroplasty as an outpatient procedure using a continuous infraclavicular nerve block at home: a prospective case report. Reg Anesth Pain Med (2006) 1.67
Polymerase chain reaction (PCR) amplification of parvoviral DNA from the brains of dogs and cats with cerebellar hypoplasia. J Vet Intern Med (2003) 1.57
The structural basis for the large powerstroke of myosin VI. Cell (2007) 1.56
Kinetic characterization of the weak binding states of myosin V. Biochemistry (2002) 1.46
Myosin IIb is unconventionally conventional. J Biol Chem (2003) 1.45
Interhead distance measurements in myosin VI via SHRImP support a simplified hand-over-hand model. Biophys J (2005) 1.43
Magnesium regulates ADP dissociation from myosin V. J Biol Chem (2004) 1.42
Myosin VI dimerization triggers an unfolding of a three-helix bundle in order to extend its reach. Mol Cell (2009) 1.42
Ambulatory continuous posterior lumbar plexus nerve blocks after hip arthroplasty: a dual-center, randomized, triple-masked, placebo-controlled trial. Anesthesiology (2008) 1.42
Correction of clinical manifestations of canine mucopolysaccharidosis I with neonatal retroviral vector gene therapy. Mol Ther (2007) 1.42
Kinetic mechanism of blebbistatin inhibition of nonmuscle myosin IIb. Biochemistry (2004) 1.40
Viral expression of insulin-like growth factor-I enhances muscle hypertrophy in resistance-trained rats. J Appl Physiol (1985) (2004) 1.40
The unique insert in myosin VI is a structural calcium-calmodulin binding site. Proc Natl Acad Sci U S A (2004) 1.38
Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension (2008) 1.37
Apelin has in vivo inotropic effects on normal and failing hearts. Circulation (2004) 1.37
Transcriptional pathways associated with skeletal muscle disuse atrophy in humans. Physiol Genomics (2007) 1.35
Chronic administration of membrane sealant prevents severe cardiac injury and ventricular dilatation in dystrophic dogs. J Clin Invest (2010) 1.34
Cargo binding induces dimerization of myosin VI. Proc Natl Acad Sci U S A (2009) 1.34
Ambulatory continuous interscalene nerve blocks decrease the time to discharge readiness after total shoulder arthroplasty: a randomized, triple-masked, placebo-controlled study. Anesthesiology (2006) 1.31
The unique insert at the end of the myosin VI motor is the sole determinant of directionality. Proc Natl Acad Sci U S A (2007) 1.30
Patterning, prestress, and peeling dynamics of myocytes. Biophys J (2004) 1.29
Functional role of loop 2 in myosin V. Biochemistry (2004) 1.29
Relationships of thigh muscle contractile and non-contractile tissue with function, strength, and age in boys with Duchenne muscular dystrophy. Neuromuscul Disord (2011) 1.27
Canine X-linked muscular dystrophy in Japan (CXMDJ). Exp Anim (2003) 1.27
Rescue of dystrophic skeletal muscle by PGC-1α involves a fast to slow fiber type shift in the mdx mouse. PLoS One (2012) 1.26
Upregulation of elastase activity in aorta in mucopolysaccharidosis I and VII dogs may be due to increased cytokine expression. Mol Genet Metab (2009) 1.25
Age-related differences in lower-limb muscle cross-sectional area and torque production in boys with Duchenne muscular dystrophy. Arch Phys Med Rehabil (2010) 1.24
Myosin Va and myosin VI coordinate their steps while engaged in an in vitro tug of war during cargo transport. Proc Natl Acad Sci U S A (2011) 1.23
Myosin VI undergoes a 180 degrees power stroke implying an uncoupling of the front lever arm. Proc Natl Acad Sci U S A (2009) 1.23
Skeletal muscles of ambulant children with Duchenne muscular dystrophy: validation of multicenter study of evaluation with MR imaging and MR spectroscopy. Radiology (2013) 1.22
Hydrodynamic limb vein injection of adeno-associated virus serotype 8 vector carrying canine myostatin propeptide gene into normal dogs enhances muscle growth. Hum Gene Ther (2009) 1.21
Stromal cell-derived factor and granulocyte-monocyte colony-stimulating factor form a combined neovasculogenic therapy for ischemic cardiomyopathy. J Thorac Cardiovasc Surg (2005) 1.20
Adhesion-contractile balance in myocyte differentiation. J Cell Sci (2004) 1.20
An intronic LINE-1 element insertion in the dystrophin gene aborts dystrophin expression and results in Duchenne-like muscular dystrophy in the corgi breed. Lab Invest (2010) 1.20
Unregulated smooth-muscle myosin in human intestinal neoplasia. Proc Natl Acad Sci U S A (2008) 1.20
Calcium functionally uncouples the heads of myosin VI. J Biol Chem (2003) 1.18
Percutaneous transendocardial delivery of self-complementary adeno-associated virus 6 achieves global cardiac gene transfer in canines. Mol Ther (2008) 1.18
Age-related differences in lower extremity tissue compartments and associations with physical function in older adults. Exp Gerontol (2011) 1.14
Interstitial myocardial fibrosis in a captive chimpanzee (Pan troglodytes) population. Comp Med (2008) 1.14
Long-term skeletal muscle protection after gene transfer in a mouse model of LGMD-2D. Mol Ther (2007) 1.13
Kinematics of gait in golden retriever muscular dystrophy. Neuromuscul Disord (2009) 1.13
Changes in muscle T2 and tissue damage after downhill running in mdx mice. Muscle Nerve (2011) 1.13
Relative contributions of muscle activation and muscle size to plantarflexor torque during rehabilitation after immobilization. J Orthop Res (2006) 1.13
Molecular extensibility of mini-dystrophins and a dystrophin rod construct. J Mol Biol (2005) 1.13
Participation and quality of life in children with Duchenne muscular dystrophy using the International Classification of Functioning, Disability, and Health. Health Qual Life Outcomes (2012) 1.12
Total knee arthroplasty as an overnight-stay procedure using continuous femoral nerve blocks at home: a prospective feasibility study. Anesth Analg (2006) 1.12
Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol Ther (2002) 1.11
Mutation of smooth muscle myosin causes epithelial invasion and cystic expansion of the zebrafish intestine. Dev Cell (2005) 1.11
Changes in inorganic phosphate and force production in human skeletal muscle after cast immobilization. J Appl Physiol (1985) (2004) 1.10
Systemic myostatin inhibition via liver-targeted gene transfer in normal and dystrophic mice. PLoS One (2010) 1.10
Rare, nonsynonymous variant in the smooth muscle-specific isoform of myosin heavy chain, MYH11, R247C, alters force generation in the aorta and phenotype of smooth muscle cells. Circ Res (2012) 1.10
Nonsense suppression activity of PTC124 (ataluren). Proc Natl Acad Sci U S A (2009) 1.09
Peptide-based inhibition of NF-κB rescues diaphragm muscle contractile dysfunction in a murine model of Duchenne muscular dystrophy. Mol Med (2011) 1.09
Noninvasive monitoring of gene correction in dystrophic muscle. Magn Reson Med (2005) 1.08
Viral gene transfer of the antiapoptotic factor Bcl-2 protects against chronic postischemic heart failure. Circulation (2002) 1.08
A phase I trial of adeno-associated virus serotype 1-γ-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C. Brain (2012) 1.08
Exon-skipped dystrophins for treatment of Duchenne muscular dystrophy: mass spectrometry mapping of most exons and cooperative domain designs based on single molecule mechanics. Cytoskeleton (Hoboken) (2010) 1.08